Priority 16 from the Hyperemesis Gravidarum PSP
| UNCERTAINTY: How does hyperemesis gravidarum impact on a person's (and their family's) quality of life? How does quality and efficacy of treatment impact that effect? (JLA PSP Priority 16) | |
|---|---|
| Overall ranking | 16 |
| JLA question ID | 0090/16 |
| Explanatory note | Not available for this PSP |
| Evidence |
Negative effects identified in a qualitative systematic review ref: Dean C, Bannigan K, Marsden J. Reviewing the effect of hyperemesis gravidarum on women’s lives and mental health. British Journal of Midwifery. 2018;26(2): Plus further studies since then add to evidence base. However, no evidence identified on how quality and efficacy of treatments mitigate or exacerbate the effect. |
| Health Research Classification System category | Reproductive health and childbirth |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | What is the range of difference in quality of life for patients as linked to the medicines they are given? |
| Submitted by | Patients x 3 ~ Healthcare professionals x 2 ~ Organisational representatives x 2 |
| PSP information | |
|---|---|
| PSP unique ID | 0090 |
| PSP name | Hyperemesis Gravidarum |
| Total number of uncertainties identified by this PSP. | 65 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 9 October 2019 |